Moreover, these preclinical findings have corresponded with clinical data from human cancer patients that has positively correlated cGAS/STING activation with the presence of tumor infiltrating T lymphocytes (i.e. T cells) (15) as well as T cell–inflamed tumors with increased overall survival (16) and responsiveness to ICB therapy (17, 18). This evidence concerns the gene CGAS and cancer.